Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Continued here:
Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

Related Post